Merck, Glenmark Cut Deal With End Payors Before Zetia Trial
Drug companies Merck and Glenmark Pharmaceuticals have reached their second settlement during jury selection for a trial on claims of an anticompetitive pay-for-delay settlement in 2010 over the cholesterol drug Zetia,...To view the full article, register now.
Already a subscriber? Click here to view full article